Supplemental Analyses of GALACTIC-HF Left: Forest plot of the primary composite endpoint for subgroups of patients with lower left ventricular...
Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021Sofpironium bromide gel, 5% (ECCLOCK®)...
TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce that...
Leveraging NextGen® Population Health Solutions, Clinically Integrated Network Improves Quality of Patient Care While Exceeding Its Savings Objectives for Two...
LONDON--(BUSINESS WIRE)--$LIVN--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s...
VANCOUVER, BC / ACCESSWIRE / December 7, 2020 / Eyam Vaccines and Immunotherapeutics (EYAM) announced that a License Agreement has...
- ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively - - cGVHD Key...
~Five presentations related to Kiadis’ K-NK cell therapy platform will be presented at the 62nd American Society of Hematology (ASH)...
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeksCPI-0610 demonstrated...
- 9 of 14 Patients Showed Reduction in Tumor Size, Including Two Recently Reported Complete Responses - - Company to...
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call...
Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host...
Long-term follow-up data from the phase III MURANO trial showed sustained progression-free survival with fixed-duration Venclexta/Venclyxto plus MabThera/Rituxan MURANO and...
Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit Additional data, including EEG findings, support prior initial indications...
- Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion -...
First Reported Allogeneic CAR T Data in Multiple Myeloma Highlights Initial Safety and Efficacy in Heavily Pretreated, Refractory PatientsIn the...
Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies IND filing for...
Lead immuno-oncology development candidate NTLA-5001 shows high anti-tumor activity as promising cancer treatment in proof-of-concept mouse models of acute leukemiasProprietary...
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR...
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the...